Want to see TSE:PHRX full AI Analyst Report?
Top Page
Pharmadrug
(PHRX)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.01
▲(0.00% Upside)
Action:Reiterated
Date:09/06/26
The score is primarily driven down by weak financial performance (minimal revenue, ongoing losses, and negative equity) despite some improvement in cash burn. Technical indicators add modest downside bias (negative MACD and price below longer-term moving averages), while valuation is not meaningfully attractive due to negative earnings and no dividend support.
Positive Factors
Improved cash burn
Cash burn has improved materially from prior years, reducing the immediate pace of liquidity depletion. Although cash flow remains negative, a lower burn rate can extend funding runway and create more time for management to improve operations or secure financing.
Negative Factors
No meaningful revenue scale
An effectively nonexistent revenue base prevents the company from demonstrating product demand, operating scale, or a durable commercial engine. Negative gross profit further suggests current sales do not cover direct costs, leaving fixed expenses and future development dependent on outside funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved cash burn
Cash burn has improved materially from prior years, reducing the immediate pace of liquidity depletion. Although cash flow remains negative, a lower burn rate can extend funding runway and create more time for management to improve operations or secure financing.
Read all positive factors
Pharmadrug (PHRX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$671.07K
Dividend YieldN/A
Average Volume (3M)29.64K
Price to Earnings (P/E)―
Beta (1Y)-0.77
Revenue GrowthN/A
EPS Growth-62.50%
CountryCA
Employees9
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding134,214,390
10 Day Avg. Volume36,720
30 Day Avg. Volume29,642
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-0.92
Price to Sales (P/S)0.00
P/FCF Ratio-18.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pharmadrug Business Overview & Revenue Model
Company Description
Pharmadrug Inc., a Toronto-based specialty pharmaceutical firm, is dedicated to the research, development, and market introduction of controlled substances and natural therapeutics, such as psychedelics, cannabis, and other approved compounds deri...
Pharmadrug Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.01K |
| Gross Profit | -50.24K | -50.24K | -50.24K | -26.22K | -2.26K | -2.15K |
| EBITDA | -230.10K | -71.98K | -549.04K | -1.33M | -2.34M | -4.21M |
| Net Income | -641.11K | -383.38K | -793.27K | -13.20M | -8.88M | -5.87M |
Balance Sheet | ||||||
| Total Assets | 752.22K | 551.66K | 711.80K | 1.20M | 12.11M | 19.52M |
| Cash, Cash Equivalents and Short-Term Investments | 28.36K | 23.24K | 75.04K | 423.06K | 329.24K | 1.30M |
| Total Debt | 1.71M | 1.52M | 1.35M | 1.77M | 1.42M | 866.37K |
| Total Liabilities | 2.46M | 2.20M | 1.96M | 2.66M | 3.28M | 2.66M |
| Stockholders Equity | -1.80M | -1.76M | -1.40M | -1.70M | 8.84M | 16.87M |
Cash Flow | ||||||
| Free Cash Flow | -89.56K | -87.51K | -768.60K | -671.88K | -2.26M | -4.17M |
| Operating Cash Flow | -89.56K | -87.51K | -756.62K | -671.88K | -2.26M | -4.13M |
| Investing Cash Flow | 0.00 | 0.00 | -11.98K | 995.04K | 77.58K | 1.48M |
| Financing Cash Flow | 94.86K | 0.00 | 321.56K | 225.51K | 843.25K | 776.97K |
Pharmadrug Technical Analysis
Negative
0.01
Price Trends
0.01
Negative
0.01
Negative
0.01
Negative
Market Momentum
>-0.01
Negative
45.03
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PHRX, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.03 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PHRX.
Pharmadrug Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | C$10.46M | -1.04 | 288.66% | ― | ― | -162.50% | |
44 Neutral | C$10.35M | -8.22 | -19.37% | ― | -19.20% | 42.54% | |
41 Neutral | C$671.07K | -0.93 | 37.95% | ― | ― | -62.50% | |
40 Underperform | C$596.95K | -0.07 | -127.50% | ― | -53.86% | 36.41% |
* Healthcare Sector Average
TSE:PHRX
Pharmadrug
0.01
0.00
0.00%
TSE:RVV
Revive Therapeutics
0.03
<0.01
25.00%
TSE:INNO
InnoCan Pharma
2.35
-10.20
-81.27%
TSE:RAMM
Ramm Pharma
0.01
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.